This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
New York-based Bristol-Myers Squibb is a one of the leading global specialty bio-pharmaceutical companies focused on the development of treatments targeting serious diseases. Backed by its blockbuster immune-oncology drug, Opdivo, Bristol-Myers has a strong oncology portfolio, consisting of other drugs like Revlimid, Sprycel, Yervoy and Empliciti. Beyond oncology, the company has important immunology and cardiovascular drugs like Orencia and Eliquis, which diversify its portfolio. Notably, in the cardiovascular space, Eliquis is now the global leading oral anti-coagulant drug. The company continues to experience growth in both the Eliquis brand and the market, while also advancing its Factor XIa inhibitor program..
Bristol-Myers (BMY) Opdivo Gets Approval for Liver Cancer
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA has approved immuno-oncology drug Opdivo for liver cancer.
Pharma Stock Roundup: Pfizer Files Suit against J&J, Supernus Hit by Study Update
by Arpita Dutt
Industry heavyweights like Pfizer (PFE) and Johnson & Johnson were in the news this week related to a lawsuit while Glaxo got FDA approval for a key drug.
Roche's (RHHBY) Tecentriq Studies Put on Partial Hold by FDA
by Zacks Equity Research
Roche Holdings AG (RHHBY) announced that the FDA has put a partial clinical hold on a phase Ib and phase I/II b trials evaluating immunotherapy drug Tecentriq.
Oncology Space in Focus this Week on ESMO Presentations
by Zacks Equity Research
There were multiple presentations at European Society for Medical Oncology 2017 Congress. AstraZeneca's lung cancer study data was positive and so was Bristol-Myers's melanoma candidate.
Bristol-Myers (BMY) Collaborates With Halozyme for ENHANZE
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) enters into a collaboration and license agreement with Halozyme Therapeutics, Inc. (HALO).
Pharma Stock Roundup: Achillion Slumps on End of HCV Deal, Teva Gets a New CEO
by Arpita Dutt
Key highlights this week include Teva's (TEVA) CEO announcement and the FDA approval of the first cancer biosimilar.
Nektar (NKTR) Starts PROPEL Combo Study for Cancer Candidate
by Zacks Equity Research
Nektar (NKTR) initiates phase I/II combo study on lead candidate NKTR-214 along with Tecentriq and Keytruda. The trial complements Nektar's ongoing PIVOT research clubbed with Opdivo.
Bristol-Myers Reports Positive Results from Melanoma Study
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced encouraging results from a phase III study, CheckMate -238, on Opdivo.
Company News For Sep 12, 2017
by Zacks Equity Research
Companies in the news are: TEVA,BMY,EFX,FB
Bristol-Myers' Opdivo Study Meets Early Success, Stock Up
by Zacks Equity Research
Bristol-Myers' (BMY) phase III study evaluating Opdivo plus Yervoy successfully met its co-primary endpoints and thus was stopped earlier than expected.
Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018
by Arpita Dutt
Key highlights this week include Eli Lilly and Company's (LLY) decision to cut the work force and streamline operations and Merck's efforts to strengthen its immune-oncology franchise.
Bristol-Myers' (BMY) Opdivo's Myeloma Studies Put on Hold
by Zacks Equity Research
Bristol-Myers Squibb Company (BMY) announced that the FDA put a partial clinical hold on three clinical trials, investigating Opdivo-based combinations in patients with relapsed or refractory multiple myeloma.
AbbVie Submits NDA for Endometriosis Candidate to the FDA
by Zacks Equity Research
AbbVie Inc. (ABBV) and partner Neurocrine Biosciences announced that the new drug application (NDA) for their pipeline candidate, elagolix, has been submitted to the FDA.
4 Drug Stocks Worth a Look on Promising Cancer Pipeline
by Zacks Equity Research
Cancer is the second most common cause of death in the U.S. preceded only by heart disease. We discuss four pharma giants, which possess the industry's strongest oncology pipeline portfolios.
Key FDA Regulatory Events to Watch Out for in Sep 2017
by Arpita Dutt
Will the FDA follow the recommendation of its advisory panel and give its nod to Amgen (AMGN) and Mylan's biosimilars?
Incyte (INCY) Reports Positive Data on Epacadostat/Keytruda
by Zacks Equity Research
Incyte Corporation (INCY) announced new and updated data from the ongoing phase I/II ECHO-202 trial on pipeline candidate epacadostat with Keytruda.
Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe
by Zacks Equity Research
Pfizer (PFE) along with Avillion announced that the regulatory authorities in the U.S. and Europe have accepted the application for label expansion of Bosulif to include newly diagnosed patients.
Pfizer Presents Encouraging Eliquis Results in NVAF Patients
by Zacks Equity Research
Pfizer (PFE) and partner Bristol-Myers presented data on Eliquis which showed the potential of the drug in reducing stroke and systemic embolism in NVAF patients undergoing cardioversion.
Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug
by Arpita Dutt
It was a pretty slow week with key highlights including regulatory updates from companies like Roche (RHHBY) and Novartis.
Celldex Ends Phase II Enrollment for Breast Cancer Candidate
by Zacks Equity Research
Celldex (CLDX) announces completion of enrollment in METRIC, a phase IIb study, evaluating glembatumumab vedotin for breast cancer treatment.
Here's Why Clovis Stock Is Up Almost 60% So Far in 2017
by Zacks Equity Research
Clovis Oncology (CLVS) stock is on the rise. The company's only approved drug Rubraca is off to an impressive start and is nearing label expansion approval.
Gilead (GILD) HCV Drug Vosevi Receives Approval in Canada
by Zacks Equity Research
Gilead Sciences, Inc.'s (GILD) HCV portfolio receives a boost with the approval of Vosevi in Canada.
Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo
by Arpita Dutt
Key highlights this week in the pharmaceutical sector include the launch of a drug pricing probe, a resignation from the President's manufacturing council and data on Bristol-Myers' (BMY) Opdivo.
Exelixis Submits sNDA for Kidney Cancer Drug Cabometyx
by Zacks Equity Research
Exelixis, Inc. (EXEL) submitted its supplemental New Drug Application (sNDA) to the FDA for Cabometyx tablets for patients with previously untreated kidney cancer.
FDA Accepts Portola's (PTLA) BLA Resubmission for AndexXa
by Zacks Equity Research
FDA acknowledges Portola's (PTLA) resubmitted BLA for AndexXa to raise hopes for an urgent need of antidotes for Factor Xa inhibitors in the market.